RIA Advisory Group LLC Takes $223,000 Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

RIA Advisory Group LLC purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 442 shares of the company’s stock, valued at approximately $223,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of IDXX. Crewe Advisors LLC bought a new position in IDEXX Laboratories during the 1st quarter worth $26,000. Ridgewood Investments LLC acquired a new stake in IDEXX Laboratories during the second quarter worth about $27,000. Institutional & Family Asset Management LLC bought a new position in IDEXX Laboratories in the 2nd quarter valued at about $28,000. E Fund Management Hong Kong Co. Ltd. raised its position in shares of IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after buying an additional 57 shares in the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 750.0% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after acquiring an additional 60 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $420.91 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. IDEXX Laboratories, Inc. has a 52 week low of $404.74 and a 52 week high of $583.39. The firm has a market cap of $34.47 billion, a PE ratio of 40.59, a price-to-earnings-growth ratio of 3.67 and a beta of 1.36. The firm’s fifty day moving average is $468.32 and its 200-day moving average is $482.73.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million for the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.53 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on IDXX. Barclays decreased their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. JPMorgan Chase & Co. lowered their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Piper Sandler restated a “neutral” rating and issued a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. BTIG Research initiated coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 price objective for the company. Finally, Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $552.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.